Determination of the Relative Efficacy of Eicosapentaenoic Acid and Docosahexaenoic Acid for Anti-Cancer Effects in Human Breast Cancer Models

Int J Mol Sci. 2017 Dec 4;18(12):2607. doi: 10.3390/ijms18122607.

Abstract

Epidemiological studies have associated high fish oil consumption with decreased risk of breast cancer (BC). n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish and fish oils exert anti-cancer effects. However, few studies have examined the relative efficacy of EPA and DHA alone and in mixtures on BC subtypes. This was the objective of the present review, as this research is a necessity for the translation of findings to human health and disease. The literature suggests that DHA has a greater anti-cancer effect in triple negative BC (TNBC). In estrogen positive (ER+) BC, DHA has a greater effect on cell viability, while both fatty acids have similar effects on apoptosis and proliferation. These effects are associated with preferential uptake of DHA into TNBC lipid rafts and EPA in ER+ BC. EPA:DHA mixtures have anti-cancer activity; however, the ratio of EPA:DHA does not predict the relative incorporation of these two fatty acids into membrane lipids as EPA appears to be preferentially incorporated. In summary, DHA and EPA should be considered separately in the context of BC prevention. The elucidation of optimal EPA:DHA ratios will be important for designing targeted n-3 LCPUFA treatments.

Keywords: ER+; HER2+; Triple Negative Breast Cancer; docosahexaenoic acid; eicosapentaenoic acid; epidermal growth factor receptor; lipid rafts; membranes.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Dietary Fats
  • Docosahexaenoic Acids / therapeutic use*
  • Eicosapentaenoic Acid / therapeutic use*
  • ErbB Receptors / metabolism
  • Humans

Substances

  • Dietary Fats
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • ErbB Receptors